Food and Drug Administration (FDA) approves AMX0035 (Amylyx) for the American market
During a meeting of the FDA’S Peripheral and Central Nervous System Drugs…
![Stay in [u]touch[/u]](/static/paper-plane.svg)
Measuring treatment effects based on patient preference
To evaluate the effect of an investigational drug in ALS clinical trials,…
TRICALS Enrols First Participants in Phase 3 MAGNET platform trial for ALS
TRICALS (the Treatment Research Initiative to Cure ALS), in collaboration with ALS…
USA: new law promises $100 million for ALS research
A new law has been passed in the United States to give…
Congratulations to our TRICALS colleagues as UK Government invests £50 million to find a cure for ALS
The UK government has recently announced that £50 million will be invested…
ADORE trial enrolls first patient
The pharmaceutical company Ferrer has announced that the first patient has been…
First participants enrolled in PHOENIX trial
Amylyx Pharmaceuticals, Inc. today announced that the first participants have been dosed…
A road map for digital health care technology in MND
The COVID-19 pandemic has had an important impact on the development and…
The Lalji Family ALS Award
The Lalji Family ALS Award is a global prize celebrating excellence in…
More patients eligible for clinical trials through innovative study design
Due to a new study design for clinical trials, more ALS patients…